Nurix Therapeutics (NASDAQ:NRIX) Insider Sells $100,143.96 in Stock

Nurix Therapeutics, Inc. (NASDAQ:NRIX) insider Gwenn Hansen sold 4,111 shares of Nurix Therapeutics stock in a transaction that occurred on Tuesday, August 4th. The shares were sold at an average price of $24.36, for a total value of $100,143.96. Following the completion of the sale, the insider directly owned 117,227 shares in the company, valued at $2,855,649.72. This represents a 3.39% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Gwenn Hansen also recently made the following trade(s):

• On Wednesday, August 5th, Gwenn Hansen sold 4,356 shares of Nurix Therapeutics stock. The shares were sold at an average price of $25.00, for a total value of $108,900.00.
• On Thursday, July 30th, Gwenn Hansen sold 3,847 shares of Nurix Therapeutics stock. The stock was sold at an average price of $23.38, for a total transaction of $89,942.86.
• On Thursday, June 25th, Gwenn Hansen sold 5,394 shares of Nurix Therapeutics stock. The shares were sold at an average price of $20.00, for a total transaction of $107,880.00.

Nurix Therapeutics Trading Up 1.2%

NRIX stock opened at $25.53 on Friday. The company’s 50-day moving average price is $21.26 and its 200 day moving average price is $18.06. Nurix Therapeutics, Inc. has a 52 week low of $8.19 and a 52 week high of $25.89. The company has a market cap of $2.65 billion, a P/E ratio of -7.40 and a beta of 1.79.

Nurix Therapeutics (NASDAQ:NRIX) last posted its quarterly earnings results on Thursday, July 9th. The company reported ($0.81) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.73) by ($0.08). The company had revenue of $9.04 million for the quarter, compared to analyst estimates of $15.29 million. Nurix Therapeutics had a negative net margin of 928.44% and a negative return on equity of 76.09%. On average, equities research analysts expect that Nurix Therapeutics, Inc. will post -2.84 earnings per share for the current year.

Analysts Set New Price Targets

A number of research firms have commented on NRIX. Wall Street Zen upgraded Nurix Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday. Truist Financial raised their price target on Nurix Therapeutics from $32.00 to $34.00 and gave the company a “buy” rating in a research report on Friday, July 10th. UBS Group lifted their price target on Nurix Therapeutics from $23.00 to $31.00 and gave the stock a “buy” rating in a research note on Wednesday, July 22nd. HC Wainwright boosted their price objective on shares of Nurix Therapeutics from $32.00 to $34.00 and gave the stock a “buy” rating in a research report on Friday, July 10th. Finally, Wells Fargo & Company cut shares of Nurix Therapeutics from an “overweight” rating to a “hold” rating and lowered their price objective for the company from $28.00 to $25.00 in a research note on Monday, June 8th. Thirteen investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Nurix Therapeutics currently has a consensus rating of “Moderate Buy” and an average target price of $34.00.

Institutional Investors Weigh In On Nurix Therapeutics

Large investors have recently bought and sold shares of the stock. BlackRock Inc. purchased a new position in Nurix Therapeutics during the second quarter worth $212,769,000. Vanguard Group Inc. boosted its stake in shares of Nurix Therapeutics by 32.5% during the fourth quarter. Vanguard Group Inc. now owns 5,949,512 shares of the company’s stock valued at $112,862,000 after acquiring an additional 1,460,736 shares during the last quarter. General Atlantic L.P. acquired a new stake in shares of Nurix Therapeutics during the fourth quarter valued at $92,899,000. Morgan Stanley increased its position in Nurix Therapeutics by 115.9% during the 4th quarter. Morgan Stanley now owns 4,881,069 shares of the company’s stock worth $92,594,000 after purchasing an additional 2,620,323 shares in the last quarter. Finally, Vestal Point Capital LP increased its position in Nurix Therapeutics by 35.0% during the 4th quarter. Vestal Point Capital LP now owns 4,690,000 shares of the company’s stock worth $88,969,000 after purchasing an additional 1,215,000 shares in the last quarter.

About Nurix Therapeutics

Nurix Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small-molecule therapies that harness the ubiquitin-proteasome system to selectively degrade disease-causing proteins. By modulating E3 ubiquitin ligases and related molecular machinery, Nurix aims to expand treatment options for patient populations with unmet medical needs in oncology and immunology.

The company’s pipeline includes multiple programs in various stages of development.